Lilly pessimistic on 2012 performance
Lilly is forecasting a drop in revenue and profits for 2012, as it prepares for life without its blockbuster antipsychotic Zyprexa.
Zyprexa (olanzapine) is licensed to treat schizophrenia and bipolar disorder and is Lilly’s biggest selling drug, bringing in $5 billion in 2010.
But the drug lost its patent in most major markets in October, and Lilly is predicting that generics will decimate sales, which it says will plummet by $3 billion in 2012.
To make matters worse, the expiry of Lilly’s second biggest selling drug, antidepressant Cymbalta (duloxetine) will also begin in major markets at the end of this year.
This double whammy has led Lilly to forecast 2012 revenues of between $21.8 to $22.8 billion, down from revenues of $23.08 billion in 2010.
Lechleiter said there were three key elements to the company’s ‘bridging’ strategy to overcome the losses and resume growth with new products.
“First and foremost, we are replenishing and advancing our pipeline. We’ve successfully rebuilt our mid- to late-stage pipeline to position Lilly for growth post-2014, with 12 assets now in Phase III, exceeding our goal of 10 by the end of 2011.
“Second, we’re investing to drive growth in the key brands that don’t lose patent protection during this period and in our countercyclical growth engines that don’t have the same cycle of patent expirations as our US and European pharma businesses. These include Japan, select emerging markets and our animal health business.
“Third, we continue to drive productivity gains across our business to fund the R&D necessary to fuel our future growth, recapitalise our physical assets and maintain our dividend at least at its current level.”
Lilly has already said that it wants to maintain its R&D budget – where other firms are making cuts – and Lechleiter is hoping this will pay off in the long term.
Lilly made a number of job cuts in 2011, including a 14% reduction in staff at its Kinsale plant in Ireland, but based on this week’s forecast, Lilly’s employees can breathe a little easier this year.
As well as predicting lower revenue, the firm also said it expects lower profits as it is not planning to make spending cuts to make up for the loss on income.
Barclays Capital analyst Anthony Butler told Bloomberg: “This may be Lilly saying, ‘We’ve cut as much as we’re going to cut, and we’re going to maintain research and development at a fairly healthy level.’”
This week’s predictions come ahead of Lilly’s full-year results for 2011, which will be announced on 31 January.
Lilly has confirmed that it expects to meet or exceed its current earnings per share guidance for 2011.
- Lilly three strikes in three years not out in Teva patent challenge
- MSD and Lilly announce immuno-oncology collaboration
- FDA approves Lilly/Boehringer Ingelheim type-2 diabetes drug
- Eli Lilly showcases emerging pipeline to investors
- FDA issues warning about rare, but serious, side effect in Lilly antipsychotic drug